Literature DB >> 8341291

Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line.

B Pardo1, M A Mena, S Fahn, J García de Yébenes.   

Abstract

Levodopa, at concentrations of 0.25 x 10(-4) M or larger, is toxic for the human neuroblastoma cell NB69. Toxicity is associated with high levels of quinones, increased activity of complex II-III, and lack of changes of complex I of the mitochondrial respiratory chain. Deprenyl, which does not alter the production of quinones, has a partial protective effect. Tocopherol, 23 or 115 x 10(-6) M, lacks significant preventive effect on levodopa toxicity, but ascorbic acid, 10(-3) M, prevents levodopa toxicity and quinone formation. Deprenyl, 10(-4) M, provides additional protection in cultures treated with levodopa and ascorbic acid. Our results indicate that ascorbic acid and deprenyl prevent levodopa neurotoxicity by unrelated mechanisms. Both compounds should be considered as complementary drugs to test for slowing the progression of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8341291     DOI: 10.1002/mds.870080305

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  13 in total

Review 1.  Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Biochem Pharmacol       Date:  2014-01-04       Impact factor: 5.858

2.  Ascorbic acid efficiently enhances neuronal synthesis of norepinephrine from dopamine.

Authors:  James M May; Zhi-Chao Qu; Rafal Nazarewicz; Sergey Dikalov
Journal:  Brain Res Bull       Date:  2012-09-26       Impact factor: 4.077

Review 3.  Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?

Authors:  M G Murer; R Raisman-Vozari; O Gershanik
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 4.  Does levodopa accelerate Parkinson's disease?

Authors:  T Simuni; M B Stern
Journal:  Drugs Aging       Date:  1999-06       Impact factor: 3.923

Review 5.  Optimising levodopa therapy for the management of Parkinson's disease.

Authors:  Fabrizio Stocchi
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

Review 6.  Epidemiology of Alzheimer disease.

Authors:  Christiane Reitz; Carol Brayne; Richard Mayeux
Journal:  Nat Rev Neurol       Date:  2011-02-08       Impact factor: 42.937

Review 7.  Contributions and Limitations of Mitochondria-Targeted and Non-Targeted Antioxidants in the Treatment of Parkinsonism: an Updated Review.

Authors:  Priyajit Banerjee; Ishita Saha; Diptendu Sarkar; Arpan Kumar Maiti
Journal:  Neurotox Res       Date:  2022-04-07       Impact factor: 3.911

Review 8.  The role of astroglia on the survival of dopamine neurons.

Authors:  María Angeles Mena; Sonsoles de Bernardo; Maria José Casarejos; Santiago Canals; Eulalia Rodríguez-Martín
Journal:  Mol Neurobiol       Date:  2002-06       Impact factor: 5.590

Review 9.  Levodopa in the treatment of Parkinson's disease: an old drug still going strong.

Authors:  Werner Poewe; Angelo Antonini; Jan Cm Zijlmans; Pierre R Burkhard; François Vingerhoets
Journal:  Clin Interv Aging       Date:  2010-09-07       Impact factor: 4.458

10.  Dopamine Cytotoxicity Involves Both Oxidative and Nonoxidative Pathways in SH-SY5Y Cells: Potential Role of Alpha-Synuclein Overexpression and Proteasomal Inhibition in the Etiopathogenesis of Parkinson's Disease.

Authors:  Kalpita Banerjee; Soumyabrata Munshi; Oishimaya Sen; Vishmadeb Pramanik; Tapasi Roy Mukherjee; Sasanka Chakrabarti
Journal:  Parkinsons Dis       Date:  2014-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.